William Blair Issues Negative Estimate for Nkarta Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Equities researchers at William Blair reduced their Q2 2025 earnings estimates for shares of Nkarta in a research report issued on Thursday, May 15th. William Blair analyst S. Corwin now forecasts that the company will earn ($0.50) per share for the quarter, down from their prior estimate of ($0.45). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.95) EPS.

A number of other equities research analysts have also recently commented on NKTX. Needham & Company LLC reduced their price target on shares of Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. Finally, Stifel Nicolaus reduced their price objective on shares of Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $14.67.

Nkarta Stock Performance

Shares of NASDAQ NKTX opened at $1.70 on Monday. Nkarta has a 52-week low of $1.31 and a 52-week high of $8.23. The firm has a 50 day moving average price of $1.79 and a two-hundred day moving average price of $2.18. The stock has a market cap of $120.63 million, a P/E ratio of -0.90 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01.

Institutional Investors Weigh In On Nkarta

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. bought a new stake in shares of Nkarta in the 4th quarter worth approximately $30,000. Sequoia Financial Advisors LLC purchased a new position in Nkarta during the 4th quarter valued at $31,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Nkarta in the 1st quarter worth about $32,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta in the 4th quarter worth about $37,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Nkarta in the 4th quarter worth about $45,000. 80.54% of the stock is currently owned by institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.